Facebook Twitter LinkedIn Google Plus RSS

Merck completes $4B purchase of Idenix

By ,
Merck completed its deal for Idenix Pharmaceuticals on Tuesday.
Merck completed its deal for Idenix Pharmaceuticals on Tuesday. - ()

Merck announced Tuesday that it has completed its multibillion-dollar tender offer for Idenix Pharmaceuticals, Inc.

The Whitehouse Station-based drugmaker said approximately 82.5 percent of Idenix shares were tendered at the purchase price of $24.50 per share. That means Merck will be able to formally complete the acquisition of the Massachusetts-based company Tuesday.

RELATED: Merck to acquire Mass. pharma company for nearly $4B

RELATED: Merck begins tender offer to acquire Idenix for $4B

The purchase price values Idenix at approximately $3.85 billion.

Upon completion of the deal, Idenix will become a wholly owned subsidiary of Merck, and its common stock will no longer be traded.

ALSO ON NJBIZ:

Two top Roseland executives to leave Mack-Cali

Hartz sells Secaucus office building for $69M

Onyx signs leases with Sony Music, two others

Eric Strauss

Eric Strauss

Eric Strauss is the digital content editor for NJBIZ. He has been a reporter and editor for newspapers in New Jersey and Pennsylvania, as well as for a number of websites. You can contact him at erics@njbiz.com or @acerimrat on Twitter.

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!